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Birnbaum, Khoury
Looking for BRPF1 Presence in Differentiating Osteoclast Cells
Mark Birnbaum, Nicholas Khoury

chromo/Tudor-related Pro-Trp-Trp-Pro
(PWWP) domain. This gene is very
conserved and has a critical role in
different developmental processes of
embryos as well as with tumors, which
is what interested us the most. Brpf1
was reported to have a tumor
suppressing role in malignant tumors.
This conclusion was based on the
observation that mutations in cancer
cells appeared to diminish the function
of Brpf1. However, oncogenic role of
Brpf1 is also possible in cancer, as it
can form a stable complex with MozTif2, which could lead to the
development of leukemia in humans.
So, by looking for this gene’s presence
in RANKL treated osteoclast cells, we
aimed to confirm its role in osteoclast
differentiation, which could be important
for future studies concerning BRPF1’s
role in osteoclast differentiation and
tumor suppression/promotion. While
studies have shown the RNA for BRPF1
being present in differentiating
osteoclast cells, no one has ever
confirmed the presence of BRPF1
protein itself.

Abstract:
Through this semester-long experiment,
professor Birnbaum and I attempted to
identify the presence of BRPF1
(Bromodomain And PHD Finger
Containing 1) in harvested RAW
osteoclast cells. This was done through
a series of steps, beginning with
growing RAW osteoclasts, differentiating
them, harvesting them and finally
running a Western Blot test to look for
our target protein. Unfortunately, no
major discoveries were made with this
project, but there is still reason to be
optimistic about the presence of other
members of the BRPF family (BRPF3,
BRPF4). With some knowledge on our
procedure, future researchers should be
able to note specific points that could be
tweaked for improvement to yield better
results.
Introduction:
This research was done as a part of my
senior thesis in conjunction with the
Honors Program at Merrimack College.
The results of this research paper were
disseminated at the Research and
Creative Achievement Conference on
campus. Through this semester long
research, professor Birnbaum and I built
upon the research we had done of
BRPF proteins in his Cellular Biology
class the previous semester. BRPF1 is
a protein that in humans is encoded by
the BRPF1 gene located on 3p26-p25. It
is a multivalent chromatin regulator that
recognizes different epigenetic marks
and activates three histone
acetyltransferases (Moz, Morf and
Hbo1). BRPF1 contains two PHD
fingers, one bromodomain and one

Materials and Methods:
Osteoclast growth and differentiation
using RANKL procedure: First, we
diluted 45 μL of cell media that was
combined with 5 μL of cells with 14 mL
of 20% fetal bovine serum (FBS) and
left the cells to incubate for 3 days on
one culture plate. Next, we divided the
cells in half and dispersed the 7 mL
portions between two larger culture
plates with fresh media to ensure we
had enough osteoclasts to work with.
Then, after a week of growth and refeeding (replacing 7 mL of old media
with new media every two days), the
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cells were refed one last time, but only
with 5 mL of media. The plate was then
scraped and stirred to suspend the cells
in fluid, and a portion of this mixture was
removed and counted under a
microscope using a hemocytometer and
tryptophan blue stain to predict the total
number of cells/mL of fluid. The
approximate number came out to
2,400,000 cells/mL in our counting. We
then calculated .125 μL + 10 mL to
achieve a diluted sample of 30,000
cells/mL. Upon diluting and observing
the diluted cells, they seemed too thin,
so we combined 250 μL of cells from
stock with 10 mL of media to achieve a
diluted sample of 60,000 cells/mL. This
combination of cells and media was
then put in one well of a multi-well plate
and incubated. After confirming
sufficient growth two days later, the cells
were re-fed with fresh media and
combined with 2 μL of receptor activator
of nuclear factor kappa-Β
ligand (RANKL) per well. RANKL is a
key osteoclast differentiation factor, so
we expected to see differentiation after
three more days of incubation. After
three days, a portion of the cells were
again stained with tryptophan blue and
observed under a microscope using a
hemocytometer. The cells seemed far
too dilute upon this observation (no
more than 5 cells per 4x4 grid could be
seen). It was apparent that the cells
needed to be re-plated and re-fed with
fresh media, given one more week to
grow, and be diluted to a lesser degree.
After observing these new cells once
more under a microscope, they were refed and re-plated by putting 2.5 mL of
the cell and stock solution into three
new wells on the multi-well plate. This
gave us four total wells, which we
labeled as day 0 thru day 3 for
harvesting. Day 0 was able to be

immediately harvested, as this was the
start of our 4-day interval.
Cell harvesting procedure: To harvest
the cells from their plates, we first set up
a plastic tube and put 1 protease
inhibitor tablet in it. To this we added 10
mL Radioimmunoprecipitation assay
(RIPA) Buffer and vortexed it until the
tablet had completely dissolved in
solution. Next, the well with the cells to
be harvested had its media removed
and it was washed with 2 mL of
Phosphate-buffered saline (PBS). The
PBS was then immediately removed
and 250 μL of RIPA Buffer was added to
the well. This plate was then vigorously
scraped to ensure all cells were
suspended in solution before the
solution was removed and placed in an
Eppendrof tube. This tube, containing
harvested RAW osteoclast cells that had
been treated with RANKL was our day 0
sample. The tube was placed in a -80
degree centigrade chiller for storage to
prevent denaturation until we were
ready to work with them again. Over the
next 3 days, the harvesting process was
repeated on the subsequent three plates
to give us day 1, day 2 and day 3
samples. The next step was to run a
protein assay, which required a PierceTM
BCA Protein Assay Kit.
Protein assay procedure: First, a
preparation of Diluted Albumin (BSA)
Standards had to be made. This was
done by diluting the contents of one
BSA ampule into several clean vials
(using the same diluent as the sample).
Each 1 mL ampule of 2 mg/mL BSA was
sufficient to prepare a set of diluted
standards for a working range of 252,000 μg/mL concentration. First, vials
labeled A-I loaded with the BSA were
given specified amounts of diluent,
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shown in figure 1.1 below. Next, vials AC were given different amounts of stock
solution, vials D-H were given dilutions
from other vials and vial was left without
any stock/BSA dilution. Upon doing this,
a ladder could now be made with BSA
concentrations ranging from 25- 2,000
μg/mL.

section. Day 3 harvested osteoclasts
were initially observed to have
extremely low protein levels, so a new
set of osteoclasts had to be treated with
RANKL and incubated for 3 days before
another day 3 sample could be pulled
and run through the spectrophotometer.
Once we had appropriate absorbance
readings for protein presence in all four
of our samples (day 0- day 3), we were
able to move onto preparation for the
Western Blot.
Western Blot Procedure: To execute
the final step of our procedure, the
Western Blot, we first needed to run an
electrophoresis gel. During the
electrophoresis, our negatively charged
proteins moved toward the positively
charged anode, which is what
propagates proteins in any gel to move
down through the gel. Our samples
were prepared and loaded onto a gel,
along with a standard protein ladder that
gave us a benchmark of where proteins
would end up on the gel based on their
size. This ladder ranged from 250 kDa
to 25 kDa. In order to further analyze the
proteins after they had completed a
sufficient run time (we knew it weighed
137 kDa, so we looked at the standard
that weighed 150 kDa and waited for
that to run approximately half way down
the gel), they were transferred onto a
membrane in a procedure called
blotting. This was done by putting the
gel on top of a membrane for transfer,
between two buffer-soaked filter sheets
(in order to prevent unwanted
membrane-protein interaction in the
following steps) and finally on the anode
floor of the blotting machine where it
was covered by a cathode plate and
allowed to run. To visualize our protein
of interest after the transfer was
complete, the membrane was first

Fig. 1.1
Next, a preparation of BCA working
reagent (WR) was made using the
formula (# standards + # unknowns) x
(#replicants) x (volume of WR per
sample) = total volume WR required.
The WR reagents were prepared by
mixing 50 parts of BCA Reagent A with
1 part of BCA Reagent B. 2.0 mL of this
working reagent was added to.1 mL of
both the sample to be assayed in a and
with the appropriate BSA standard in a
test tube, Next, the solution in the test
tubes was able to be transferred to
cuvettes and run through the
spectrophotometer (along with a blank
for control) to yield an absorbance rate
at 562 nm wavelength. Results of this
test can be seen in fig 1.2 in the results
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washed with TBST without milk, then it
was probed using a primary proteinspecific antibody with TBST and milk
with washes in between. Once this had
been applied, we applied a labeled
secondary antibody that would reveal
our target protein if it was present on the
membrane.
Results: Seen in fig. 1.2 are the results
of our protein assay, which gave us a
good measurement of exactly how much
protein we had in our day 0- day 3
samples. Using an excel spreadsheet,
we were able to make a graph from the
BSA concentration ladder. Off of the
protein concentration vs standard
protein average absorbances at 562 nm,
we could determine where on the graph
our protein would fall, given its
absorbance at 562 nm. This was done
by using every second number (in red)
in column A, standard protein
absorbance @ 562 nm, except for the
last number in the column, where the
first number in red was used instead
(1.944, here we used 1.489 instead
because it stayed in bounds on our
trend line). Every first number in column
A represents a cuvette that contained 20
μL of our cell solution, and every second
number represents a cuvette that
contained 100 μL of our cell solution.
The resulting concentrations of our
proteins went as follows: day 0 had a
concentration of 495 μg/mL, day 1 had a
concentration of 660 μg/mL, day 2 had a
concentration of 950 μg/mL and day 3
had a concentration of 1450 μg/mL.
Initial day 3 harvested osteoclasts (not
shown) were redone because they gave
us a 20 μL reading of .008 absorbance,
and a 100 μL reading of .027
absorbance, which would correlate to a
concentration less than 100 μg/mL
based on our standard graph.

Fig 1.2
As displayed in fig. 1.3, there is a
questionable indication of the BRPF1
protein on this Western Blot. We see our
protein standard ladder in the lane on
the far right, but there is no definitive
indication of BRPF1 presence anywhere
else on this membrane. From left to
right, we expected to see lines
somewhere between the second and
third standard lines on the ladder. The
second standard line translated to a
molecular weight of about 150 kDa, and
the third line translated to a molecular
weight of about 100 kDa. The molecular
weight of BRPF1 is approximately 137
kDa, meaning it theoretically should
have fallen somewhere between these
two lines. Furthermore, we hypothesized
to notice a pattern from left to right of
the BRPF1 containing bands getting
darker. This would have signified that as
time went on (from day 0 to day 3) there
was differentiation occurring in the
osteoclasts that promoted further
expression of the BRPF1. Instead of
seeing these results, though, we instead
saw two lines (that got fainter from day 1
to day 2). Circled in figure 1.3 are these
two possible bands that we found on
this membrane, but its reliability is
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debatable. The faintly observable band
is not near its supposed molecular
weight of 137 kDA, but rather up near
the top line of the ladder, which signifies
a molecular weight somewhere around
250 kDA. While this is a highly unlikely
position for the protein to be positioned
at, considering that the standard ladder
run on the right side of the membrane
ran reliably and without any problems, it
is a possibility that this is BRPF1. We
can say this because we used a protein
specific antibody, meaning the antibody
was tailored to only stick to BRPF1 and
nothing else. Further testing would be
required to confirm or deny this oddly
placed location of the visible band on
our membrane.

procedural changes to make that might
confirm or deny our initial hypothesis to
a greater degree. Some reasons for our
potential inability to find the protein
could be dilution beyond a threshold of
observability. Having to regrow and
harvest our day 3 samples was also an
inconvenience, as it gave us two
separately grown sets of osteoclasts
(day 0- day 2 and day 3). For
consistency in experiments like this, it is
always preferred to have all the cells
come from one batch to minimize
potential error. The largest source of
error was likely related to these
technical details. Simply put; there might
not have been enough cells, meaning
there wasn’t enough protein to give us
an accurate reading. This could go back
to the dilution of our cells (to an initial
dilution of 30,000 cells/mL and then to
60,000 cells/mL). To garner higher
protein and cell density, more cells
could have been initially added.
However, one must be careful to not
grow too many cells because this might
cause overcrowding, which means that
the osteoclasts won’t differentiate. Next
semester, Professor Birnbaum will
tackle this research with another student
to try and get more comprehensive
results and draw a more definite
conclusion on our experiment.

Fig 1.3
Conclusion: While we were not able to
get the exact results we hypothesized to
see, this does not mean that there is no
BRPF1 to be found in osteoclasts. The
presence of its RNA still supports the
proteins presence and the two bands
that we did see on the gel means we
cannot confidently rule out the incidence
of BRPF1 in our differentiated
osteoclasts. There could be some
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